Androgendeprivationstherapie beim Prostatakarzinom

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Dr. Agnes Maj-Hes

Universitätsklinik für Urologie, Comprehensive Cancer Center, Medizinische Universität Wien, AKH Wien


AutorIn: Univ.-Prof. Dr. Gero Kramer

Universitätsklinik für Urologie, Comprehensive Cancer Center, Medizinische Universität Wien, AKH Wien


Foto: felicitas matern
AutorIn: Prim. Univ.-Prof. Dr. Shahrokh F. Shariat

Universitätsklinik für Urologie, Comprehensive Cancer Center, Medizinische Universität Wien, AKH Wien


Literatur:

1 Loblaw DA et al., American Society of Clinical Oncology, Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596–605

2 Mohler JL et al., The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10:440–8

3 Chen CD et al., Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33–9

4 Titus MA et al., Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11:4653–7

5 Stanbrough M et al., Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66:2815–25

6 Locke JA et al., Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68:6407–15

7 Chang KH et al., Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108:13728–33

8 Locke JA et al., Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J Steroid Biochem Mol Biol 2009; 115:126–36

9 Leon CG et al., Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010; 70:390–400

10 Mohler JL, Titus MA, Wilson EM, Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011; 17:5844–9

11 Mohler JL et al., Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011; 71:1486–96

12 Chang KH et al., A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013; 154:1074–84

13 Messing EM et al., Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7:472–9

14 Bolla M et al., Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360:103–6

15 Pilepich MV et al., Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61:1285–90

16 Hanks GE et al., Radiation Therapy Oncology Group, Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21:3972–8

17 Abrahamsson PA, Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57:49–59

18 Isaacs JT, The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 1984; 5:1–17 1990;126:1165-1172.

19 Messing EM et al., Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl J Med 1999; 341:1781–8

20 Wirth MP et al., Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004; 45:267–70

21 Tyrrell CJ et al., Bicalutamide (,Casodex‘) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005; 76:4–10

22 Shelley MD, Kumar S, Coles B et al., Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev 2009 Nov; 35(7):540–6


SO 04|2014

Herausgeber: Univ.-Prof. Dr. Christoph Zielinski, Univ.-Prof. Dr. Markus Raderer
Publikationsdatum: 2014-12-19